<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Celltrion (068270.KS) has signed a contract manufacturing agreement with a global pharmaceutical company for the supply of drug substance. Celltrion will supply drug substance for three years from 2027 through 2029. The contract value is approximately 294.9 billion Korean won and may expand to 375.4 billion won. </p><p>Earlier in the current year, Celltrion signed a CMO contract with Eli Lilly, and with the addition of new agreement, the company's cumulative CMO order backlog surpassed 1 trillion won within the first quarter of the year. Celltrion noted that it is reviewing additional manufacturing facilities both domestically and overseas to ensure sufficient infrastructure and support growing global CDMO demand.</p><p>Celltrion shares are trading at 2,06,500 won, up 3.25%. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

CYCN

LCTX

<p>Celltrion has signed a contract manufacturing agreement with a global pharmaceutical company to supply drug substance from 2027 to 2029, valued at approximately 294.9 billion Korean won, potentially expanding to 375.4 billion won. This agreement adds to Celltrion's CMO order backlog, which has surpassed 1 trillion won. The company is also exploring additional manufacturing facilities to meet growing global demand. Celltrion shares rose by 3.25% to 206,500 won.</p>

rttnews

Cyclerion Therapeutics

SPDR S&P Biotech

Lineage Cell Therapeutics

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Cytomx Therap

iShares Biotechnology ETF

Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company